| Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors R Grosser, L Cherkassky, N Chintala, PS Adusumilli Cancer cell 36 (5), 471-482, 2019 | 359 | 2019 |
| A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti–PD-1 agent pembrolizumab PS Adusumilli, MG Zauderer, I Rivière, SB Solomon, VW Rusch, ... Cancer discovery 11 (11), 2748-2763, 2021 | 293 | 2021 |
| Complement c5a receptor facilitates cancer metastasis by altering T-cell responses in the metastatic niche SK Vadrevu, NK Chintala, SK Sharma, P Sharma, C Cleveland, ... Cancer research 74 (13), 3454-3465, 2014 | 185 | 2014 |
| Pulmonary alveolar macrophages contribute to the premetastatic niche by suppressing antitumor T cell responses in the lungs SK Sharma, NK Chintala, SK Vadrevu, J Patel, M Karbowniczek, ... The Journal of Immunology 194 (11), 5529-5538, 2015 | 163 | 2015 |
| Driving CARs on the uneven road of antigen heterogeneity in solid tumors N Chen, X Li, NK Chintala, ZE Tano, PS Adusumilli Current opinion in immunology 51, 103-110, 2018 | 102 | 2018 |
| Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: safety and preliminary efficacy in combination with anti-PD-1 agent. PS Adusumilli, MG Zauderer, VW Rusch, R O'Cearbhaill, A Zhu, D Ngai, ... Journal of Clinical Oncology 37 (15_suppl), 2511-2511, 2019 | 92 | 2019 |
| Chimeric antigen receptor (CAR) T-cell therapy for thoracic malignancies S Kiesgen, L Chicaybam, NK Chintala, PS Adusumilli Journal of Thoracic Oncology 13 (1), 16-26, 2018 | 82 | 2018 |
| Comparative analysis of assays to measure CAR T-cell-mediated cytotoxicity S Kiesgen, JC Messinger, NK Chintala, Z Tano, PS Adusumilli Nature protocols 16 (3), 1331-1342, 2021 | 69 | 2021 |
| The ribosomal protein S19 suppresses antitumor immune responses via the complement C5a receptor 1 MM Markiewski, SK Vadrevu, SK Sharma, NK Chintala, S Ghouse, ... The Journal of Immunology 198 (7), 2989-2999, 2017 | 61 | 2017 |
| Abstract CT036: A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: Safety and efficacy PS Adusumilli, MG Zauderer, VW Rusch, RE O'Cearbhaill, A Zhu, ... Cancer research 79 (13_Supplement), CT036-CT036, 2019 | 37 | 2019 |
| A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: Safety and efficacy PS Adusumilli, MG Zauderer, VW Rusch, RE O'Cearbhaill, A Zhu, ... CANCER RESEARCH 79 (13), 2019 | 32 | 2019 |
| Tumor and tumor-associated macrophage programmed death-ligand 1 expression is associated with adjuvant chemotherapy benefit in lung adenocarcinoma DJ Gross, NK Chintala, RG Vaghjiani, R Grosser, KS Tan, X Li, J Choe, ... Journal of Thoracic Oncology 17 (1), 89-102, 2022 | 20 | 2022 |
| CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials NK Chintala, D Restle, H Quach, J Saini, R Bellis, M Offin, J Beattie, ... Lung Cancer 157, 48-59, 2021 | 17 | 2021 |
| Abstract LB-378: Regional delivery of clinical-grade mesothelin-targeted CAR T cells with cell-intrinsic PD-1 checkpoint blockade: Translation to a phase I trial S Kiesgen, C Linot, HT Quach, J Saini, R Bellis, S Banerjee, Z Hou, ... Cancer Research 80 (16_Supplement), LB-378-LB-378, 2020 | 10 | 2020 |
| Novel immunotherapy clinical trials in malignant pleural mesothelioma ZE Tano, NK Chintala, X Li, PS Adusumilli Annals of translational medicine 5 (11), 2017 | 10 | 2017 |
| Globular C1q receptor (gC1qR/p32/HABP1) is overexpressed in malignant pleural mesothelioma and is associated with increased survival in surgical patients treated with chemotherapy X Li, T Eguchi, RG Aly, NK Chintala, KS Tan, MG Zauderer, FR Dembitzer, ... Frontiers in Oncology 9, 1042, 2019 | 9 | 2019 |
| Studying the role of alveolar macrophages in breast cancer metastasis SK Vadrevu, S Sharma, N Chintala, J Patel, M Karbowniczek, ... JoVE (Journal of Visualized Experiments), e54306, 2016 | 7 | 2016 |
| Correlative analysis from a phase I clinical trial of intrapleural administration of oncolytic vaccinia virus (Olvi-vec) in patients with malignant pleural mesothelioma NK Chintala, JK Choe, E McGee, R Bellis, JK Saini, S Banerjee, ... Frontiers in Immunology 14, 1112960, 2023 | 6 | 2023 |
| c-Kit signaling potentiates CAR T cell efficacy in solid tumors by CD28-and IL-2-independent co-stimulation Y Xiong, M Taleb, K Misawa, Z Hou, S Banerjee, A Amador-Molina, ... Nature Cancer 4 (7), 1001-1015, 2023 | 5 | 2023 |
| Organ-specific heterogeneity in tumor-infiltrating immune cells and cancer antigen expression in primary and autologous metastatic lung adenocarcinoma D Restle, J Dux, X Li, AJ Byun, JK Choe, Y Li, RG Vaghjiani, C Thomas, ... Journal for Immunotherapy of Cancer 11 (6), 2023 | 5 | 2023 |
